Alkermes plc (NASDAQ:ALKS) Shares Bought by Smartleaf Asset Management LLC

Smartleaf Asset Management LLC grew its position in Alkermes plc (NASDAQ:ALKS) by 558.5% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,950 shares of the company’s stock after acquiring an additional 2,502 shares during the quarter. Smartleaf Asset Management LLC’s holdings in Alkermes were worth $85,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in ALKS. Wealth Enhancement Advisory Services LLC purchased a new position in shares of Alkermes in the third quarter valued at approximately $281,000. US Bancorp DE lifted its position in shares of Alkermes by 48.8% in the third quarter. US Bancorp DE now owns 10,302 shares of the company’s stock valued at $288,000 after acquiring an additional 3,378 shares in the last quarter. Van ECK Associates Corp lifted its position in shares of Alkermes by 40.0% in the third quarter. Van ECK Associates Corp now owns 104,986 shares of the company’s stock valued at $2,924,000 after acquiring an additional 29,998 shares in the last quarter. Robeco Institutional Asset Management B.V. lifted its position in shares of Alkermes by 92.4% in the third quarter. Robeco Institutional Asset Management B.V. now owns 95,509 shares of the company’s stock valued at $2,673,000 after acquiring an additional 45,857 shares in the last quarter. Finally, Aigen Investment Management LP purchased a new position in shares of Alkermes in the third quarter valued at approximately $216,000. Hedge funds and other institutional investors own 95.21% of the company’s stock.

Insider Activity

In other news, Director Cato T. Laurencin sold 2,691 shares of Alkermes stock in a transaction on Monday, December 9th. The stock was sold at an average price of $31.85, for a total value of $85,708.35. Following the completion of the sale, the director now directly owns 23,013 shares of the company’s stock, valued at approximately $732,964.05. The trade was a 10.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, EVP Craig C. Hopkinson sold 144,419 shares of Alkermes stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $35.53, for a total value of $5,131,207.07. Following the completion of the sale, the executive vice president now directly owns 57,875 shares of the company’s stock, valued at $2,056,298.75. The trade was a 71.39 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 309,179 shares of company stock valued at $10,412,450. 4.89% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on ALKS shares. HC Wainwright restated a “neutral” rating and issued a $46.00 target price on shares of Alkermes in a research report on Thursday, February 13th. Deutsche Bank Aktiengesellschaft assumed coverage on Alkermes in a research report on Tuesday, February 11th. They set a “buy” rating and a $40.00 price objective on the stock. Mizuho lifted their price objective on Alkermes from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Wednesday, November 13th. StockNews.com upgraded Alkermes from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 13th. Finally, UBS Group upgraded Alkermes from a “sell” rating to a “neutral” rating and lifted their price objective for the stock from $21.00 to $38.00 in a research report on Tuesday, March 4th. Three equities research analysts have rated the stock with a hold rating, nine have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $38.33.

Alkermes Stock Down 0.9 %

NASDAQ:ALKS opened at $34.35 on Friday. Alkermes plc has a 52 week low of $22.90 and a 52 week high of $36.45. The company has a market capitalization of $5.59 billion, a P/E ratio of 15.83, a P/E/G ratio of 2.20 and a beta of 0.62. The stock’s fifty day moving average is $31.85 and its two-hundred day moving average is $29.64.

Alkermes (NASDAQ:ALKS) last posted its earnings results on Wednesday, February 12th. The company reported $0.92 EPS for the quarter, beating analysts’ consensus estimates of $0.81 by $0.11. Alkermes had a return on equity of 30.80% and a net margin of 23.57%. Sell-side analysts anticipate that Alkermes plc will post 1.31 earnings per share for the current fiscal year.

Alkermes Company Profile

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders.